The Effect of Impaired Glucagon Suppression in Pre-diabetes

Overview

About this study

The purpose of this study is to determine the effect of impaired postprandial glucagon suppression on postprandial glucose metabolism.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Subjects will be recruited from prior participation in studies specifically designed to correlate genotype with phenotype. We plan to contact prior participants by means of IRB-approved letters. Eligible subjects will be invited to participate in the study and to come to the CRU for a screening visit

Exclusion Criteria:

Medications that can affect glucose metabolism (to be determined by PI)
For female subjects: positive pregnancy test
Any active systemic illness, microvascular or macrovascular disease

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Adrian Vella, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials